Peripheral Arterial Disease

• Endothelial Dysfunction and Atherosclerotic Plaque Formation: Chronic exposure to risk factors (hypertension, hyperlipidemia, smoking, diabetes) causes endothelial injury and loss of normal vasodilatory function. Increased endothelial permeability allows low-density lipoprotein (LDL) accumulation in the intimal layer, where oxidation generates oxidized LDL (oxLDL). OxLDL triggers expression of monocyte adhesion molecules (ICAM-1, VCAM-1, selectins) and chemotactic proteins (MCP-1), recruiting circulating monocytes into the intima. Monocytes differentiate into macrophages and engulf oxLDL via scavenger receptors, forming lipid-laden foam cells that constitute the fatty streak—the earliest visible atherosclerotic lesion. This inflammatory process involves activation of nuclear factor-kappa B (NF-κB) pathway, perpetuating cytokine release (TNF-α, IL-1, IL-6) that amplifies vascular inflammation.

• Plaque Progression and Fibrous Cap Formation: Activated macrophages and smooth muscle cells (SMCs) migrate from the media into the intima via matrix metalloproteinase-2 and -9 activity, which degrades extracellular matrix. Within the intima, SMCs undergo phenotypic switching from a contractile to a synthetic state, proliferating and secreting collagen (Types I and III), elastin, and proteoglycans. This extracellular matrix accumulation forms a fibrous cap overlying a lipid-rich necrotic core containing cholesterol crystals, apoptotic cells, and thrombotic material. The fibrous cap's structural integrity depends on the balance between collagen synthesis (by SMCs and fibroblasts) and collagen degradation (by matrix metalloproteinases from macrophages), explaining why plaques with thin fibrous caps and large lipid cores are more prone to rupture.

• Progressive Luminal Narrowing and Flow Limitation: As the plaque grows, it encroaches upon the vascular lumen, progressively narrowing the arterial diameter. Flow limitation becomes hemodynamically significant when diameter stenosis exceeds ~50% on angiography (corresponding to ~75% area stenosis). At this threshold, the ability of distal vasculature to dilate and increase flow in response to metabolic demand becomes compromised. With increasing stenosis severity, the pressure gradient across the lesion increases according to the Hagen-Poiseuille equation (ΔP ∝ viscosity × length / radius⁴), meaning that doubling vessel narrowing creates a 16-fold increase in resistance. When stenosis exceeds 70% diameter narrowing, resting blood flow may become insufficient to meet basal metabolic demands, resulting in ischemia at rest rather than only with exertion.

• Collateral Angiogenesis and Vascular Compensation: In response to chronic flow limitation, increased shear stress and tissue hypoxia stimulate release of angiogenic factors, particularly vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). These factors promote neovascularization from preexisting collateral vessels that normally carry minimal flow. Over weeks to months, collateral vessels dilate and sprout new capillaries, establishing alternative perfusion pathways around the stenotic lesion. The adequacy of collateral development varies considerably between individuals and depends on genetic factors, ischemic stimulus duration, and inflammatory state—explaining why some patients with severe stenosis remain asymptomatic (good collaterals) while others with moderate stenosis develop claudication (poor collaterals). Chronic hypoxia-inducible factor 1-alpha (HIF-1α) stabilization in ischemic tissue further amplifies VEGF and other pro-angiogenic signals.

• Acute Thrombotic Events: Plaque rupture occurs when mechanical stress exceeds the fibrous cap's structural integrity, exposing highly thrombogenic lipid core material and tissue factor to blood. This triggers rapid platelet activation and aggregation via ADP and thromboxane A2 signaling through P2Y12 and TP receptors, and simultaneously activates the tissue factor-mediated extrinsic coagulation cascade, generating thrombin and fibrin clot. The resulting thrombus may partially occlude the artery (causing acute worsening of claudication or rest pain) or completely occlude it (causing acute limb ischemia). Systemic inflammation and atherosclerotic burden correlate with thrombotic risk, explaining why acute events frequently occur in the setting of plaque vulnerability markers (elevated inflammatory markers, negative remodeling on imaging).

• Molecular and Genetic Determinants: Genetic polymorphisms in genes regulating inflammation (IL-6, CRP), thrombosis (Factor V Leiden, prothrombin G20210A), lipid metabolism (apoE4, LDL receptor variants), and vascular function (endothelial nitric oxide synthase) modulate PAD risk and progression. Lipoprotein(a) [Lp(a)], genetically determined and largely resistant to lifestyle intervention, represents an independent PAD risk factor through prothrombotic effects and enhanced lipoprotein retention within plaques.

• Atherosclerotic Lesions (>95% of PAD): Atherosclerotic disease results from chronic exposure to traditional cardiovascular risk factors. Smoking represents the single most modifiable risk factor, with dose-dependent relationship—smokers have 10-fold higher PAD prevalence compared to never-smokers—and continue to show accelerated disease progression and higher amputation rates even after symptom onset compared to non-smokers. Smoking induces endothelial dysfunction through oxidative stress, increases platelet reactivity, elevates lipoprotein(a), and impairs collateral development. Diabetes mellitus significantly amplifies PAD risk (2-4 fold), particularly through hyperglycemia-induced vascular dysfunction, enhanced atherosclerotic plaque formation, and impaired collateral angiogenesis; notably, diabetic patients present with more extensive disease, higher rates of infrapopliteal involvement, and substantially worse outcomes. Hypertension increases PAD risk through chronic endothelial shear stress and medial vascular remodeling. Hyperlipidemia, particularly elevated LDL cholesterol and low HDL cholesterol, directly contributes to atherosclerotic plaque formation; elevated triglycerides and lipoprotein(a) confer additional risk. Age and male gender are non-modifiable risk factors, with disease prevalence doubling per decade above age 50 years in men and showing similar but somewhat later-onset patterns in women.

• Thrombophilic States: Inherited conditions including Factor V Leiden, prothrombin G20210A mutation, antithrombin deficiency, protein C deficiency, and protein S deficiency increase thrombotic risk and can precipitate early-onset or recurrent PAD, particularly in younger patients (age <50 years) presenting with acute limb ischemia. Antiphospholipid syndrome causes both arterial and venous thrombosis through mechanisms including platelet activation and tissue factor upregulation. Malignancy represents an occult thrombophilic state conferring PAD and acute thrombosis risk through tissue factor expression by cancer cells and tumor-associated macrophages.

• Inflammatory and Autoimmune Conditions: Thromboangiitis obliterans (Buerger's disease) is a distinctive inflammatory vasculitis affecting small and medium arteries of extremities, almost exclusively in heavy smokers, causing distal vessel occlusion with notably preserved proximal vessels and frequent upper extremity and visceral involvement. Takayasu arteritis and giant cell arteritis affect large elastic arteries and can present with lower extremity ischemia. Rheumatoid arthritis increases systemic inflammation and atherosclerotic burden, conferring 1.5-2 fold PAD risk. Chronic kidney disease associates with accelerated atherosclerosis through uremic toxins, anemia, hypertension, and inflammatory activation.

• Radiation Exposure: Prior therapeutic radiation to lower extremities (for malignancy) causes direct endothelial injury, fibrosis of vessel walls, and premature atherosclerosis, typically manifesting years to decades after radiation exposure.

• Ergot and Cocaine Use: Both substances cause intense vasoconstriction and direct endothelial injury, potentially precipitating acute arterial insufficiency.

• Trauma and Arterial Injury: Penetrating or blunt trauma may cause arterial dissection, thrombosis, or pseudoaneurysm formation. Iatrogenic injury from vascular procedures, cardiac catheterization, or intra-arterial drug injection may similarly compromise arterial patency.

• Asymptomatic PAD: Approximately 50% of individuals with objective evidence of PAD (abnormal ankle-brachial index) remain completely asymptomatic, particularly in older patients with sedentary lifestyles who never exceed the ischemic threshold during daily activities. These patients have significantly elevated cardiovascular event risk and warrant aggressive secondary prevention despite lack of limb symptoms.

• Intermittent Claudication: This hallmark symptom presents as reproducible exertional pain, cramping, or fatigue in the calf, thigh, or buttock that occurs with walking and is relieved by rest (typically within 5-10 minutes). The pain arises from anaerobic metabolism in exercising skeletal muscle downstream of a hemodynamically significant arterial stenosis; during exertion, muscles attempt to increase oxygen consumption but arterial inflow cannot meet metabolic demand due to flow limitation, causing lactate accumulation and ischemic discomfort. Crucially, claudication is reproducible—the same walking distance consistently precipitates symptoms—distinguishing it from atypical leg pain. Patients often describe "shopping mall syndrome," the typical scenario where symptoms appear after walking a predictable distance. The anatomic location of claudication reflects the stenosis location: calf claudication indicates superficial femoral artery (SFA) disease; thigh or buttock claudication suggests iliac disease. Buttock and hip claudication with erectile dysfunction in men is pathognomonic for Leriche syndrome (aortoiliac occlusive disease). Claudication carries relatively favorable prognosis with only ~5-10% of patients progressing to amputation over 5 years, though one-third will experience worsening symptoms and two-thirds will have cardiac or cerebrovascular events.

• Rest Pain: This ominous symptom indicates critical limb ischemia (CLI), developing when arterial insufficiency is so severe that even basal metabolic demands of resting tissue cannot be met. Rest pain typically presents as severe, burning pain in the forefoot or toes, often worst at night when horizontal positioning eliminates gravity-assisted perfusion. Patients often report symptom relief by dangling the leg over the bed (gravity increases perfusion) or sleeping upright in a chair. Rest pain represents absolute indication for urgent intervention as it signifies high amputation risk if blood flow is not restored.

• Acute Limb Ischemia: Sudden arterial occlusion due to thrombus or embolism causes abrupt onset of symptoms, classically described by the "6 P's": Pain, Pallor, Pulselessness, Paresthesias, Paralysis, and Poikilothermia (coldness). Pain is typically severe and out of proportion to examination findings early in the course. Pallor reflects absent capillary perfusion. Mottled, cyanotic skin may appear. Sensory changes (paresthesias) and motor weakness (initially foot drop) develop within hours as ischemic nerve and muscle damage progresses. This is a vascular emergency requiring intervention within 6-8 hours to prevent irreversible tissue necrosis.

• Tissue Loss and Gangrene: Progressive chronic ischemia leads to non-healing wounds, ulceration, and gangrene. Ischemic ulcers characteristically develop on pressure points (heels, lateral malleolus, metatarsal heads) with punched-out appearance, clean borders, minimal exudate, and surrounding skin that appears pale, hairless, and atrophic. Gangrene may be "dry" (mummification from slow tissue death in a demarcated area, common in chronic PAD) or "wet" (rapid necrosis with surrounding inflammation and edema, often complicated by infection and representing a surgical emergency).

• Physical Examination Findings:
• Diminished or absent pulses in femoral, popliteal, dorsalis pedis, or posterior tibial arteries on the affected side; asymmetric pulses between extremities are particularly suggestive of PAD.
• Pallor on elevation and dependent rubor/erythema: Elevation of the affected leg causes pallor (loss of perfusion-dependent color) while healthy legs maintain pink coloration; conversely, when the leg hangs dependently, it develops reactive hyperemia (dependent rubor) as compensatory vasodilation attempts to restore perfusion.
• Decreased skin temperature (coolness on palpation compared to unaffected limb).
• Atrophic skin changes: Hair loss (alopecia), smooth, shiny skin appearance, dystrophic toenails.
• Muscle atrophy in severely affected limbs due to chronic ischemia.
• Bruits over femoral or iliac arteries suggest turbulent flow through stenotic vessels.
• Capillary refill may be delayed (>2 seconds) in severely ischemic limbs.

• Atypical Presentations: Some patients present with exertional leg pain that does not fully resolve with rest (raising suspicion for CLI superimposed on chronic claudication) or with acute-on-chronic ischemia when thrombus develops in a chronically narrowed vessel. Others, particularly diabetic patients with neuropathy, may develop foot ulceration or gangrene with minimal or absent claudication symptoms because sensory loss prevents pain recognition. Asymptomatic PAD discovered on screening or incidentally remains common, particularly in sedentary individuals who never stress the affected vessels sufficiently to provoke symptoms.

• Clinical History and Risk Stratification: A detailed history focusing on exertional leg discomfort, its reproducibility, walking distance tolerated before symptom onset, symptom relief characteristics, presence of rest pain, and history of tissue loss establishes clinical suspicion for PAD. Risk factor assessment including smoking history (pack-years), diabetes duration and control, hypertension, hyperlipidemia, and prior cardiovascular events refines pretest probability. The Edinburgh Claudication Questionnaire is a validated tool identifying claudication with high sensitivity and specificity; patients answering affirmatively to leg pain with exertion, pain-free walking distance, and pain relief with rest warrant further testing.

• Ankle-Brachial Index (ABI): This non-invasive study represents the initial diagnostic test of choice for confirming PAD in patients with exertional leg symptoms or risk factors. ABI is calculated as the ratio of systolic blood pressure in the lower extremity (measured via handheld Doppler at the dorsalis pedis or posterior tibial artery) to the higher of the two brachial artery systolic pressures. Normal ABI ranges from 1.0 to 1.4 (ankle pressure slightly exceeds arm pressure due to amplification). Interpretation guidelines:
• ABI 0.91-1.0: Normal
• ABI 0.71-0.90: Mild-to-moderate PAD (usually claudication)
• ABI 0.41-0.70: Moderate-to-severe PAD (claudication or rest pain)
• ABI ≤0.40: Severe PAD (rest pain, tissue loss)
• ABI >1.4: Suggests non-

Immediate stabilization (acute limb ischemia)

• Systemic anticoagulation: unfractionated heparin IV bolus plus infusion the moment ALI is suspected, to prevent thrombus propagation while the limb is triaged — an ACC/AHA lower extremity PAD guideline recommendation. Emergent vascular surgery consultation is mandatory; viable/marginally threatened limbs (Rutherford I–IIa) may be managed with catheter-directed thrombolysis, while immediately threatened limbs (IIb, with sensory and motor loss) require open thromboembolectomy or bypass without waiting for lysis.

First-line therapy for chronic symptomatic PAD (all patients)

• Structured exercise therapy: supervised treadmill walking to near-maximal claudication pain, promoting collateral recruitment, mitochondrial efficiency, and improved endothelial NO signaling. It is the single most effective intervention for walking distance and is recommended before revascularization for claudication.
• Smoking cessation: pharmacotherapy (varenicline, bupropion, nicotine replacement) plus counseling; nothing else alters amputation and graft-patency risk as much.
• High-intensity statin (e.g., atorvastatin): symptomatic PAD is clinical ASCVD under the ACC/AHA cholesterol guideline; add ezetimibe then a PCSK9 inhibitor if LDL remains above goal in very-high-risk patients.
• Single antiplatelet therapy: aspirin or clopidogrel for symptomatic PAD (benefit in asymptomatic disease is weaker).
• Blood pressure and glycemic control: ACE inhibitor or ARB per the ACC/AHA hypertension guideline; per the ADA Standards of Care, favor an SGLT2 inhibitor or GLP-1 receptor agonist in diabetes with ASCVD.

Escalation

• Cilostazol: phosphodiesterase-3 inhibitor causing vasodilation and platelet inhibition; improves maximal walking distance in claudication.
• Low-dose rivaroxaban plus aspirin: dual-pathway inhibition reduces major adverse limb and cardiovascular events, at the cost of bleeding.

Definitive/revascularization

• Endovascular therapy (angioplasty ± stent) for lifestyle-limiting claudication refractory to medical therapy and for focal aortoiliac disease.
• Surgical bypass (autologous great saphenous vein preferred over prosthetic) for long-segment occlusion and chronic limb-threatening ischemia; primary amputation only for unsalvageable limbs.

Contraindicated/avoid

• Cilostazol in any heart failure — PDE-3 inhibitors increase mortality in HF.
• Pentoxifylline and chelation therapy: not recommended; warfarin monotherapy adds bleeding without limb benefit.
• Beta blockers are NOT contraindicated in PAD — a classic exam trap.

Disease-related

• Chronic limb-threatening ischemia: perfusion falls below resting metabolic demand; signals are rest pain relieved by dependency, non-healing ulcer, or gangrene. High amputation risk — requires urgent revascularization assessment.
• Acute limb ischemia (emergency): in-situ plaque rupture with thrombosis or cardioembolism produces the 6 P's; motor deficit or loss of Doppler arterial signal marks an immediately threatened limb and a window of only hours.
• Wet gangrene and sepsis (emergency): ischemic tissue is a culture medium; spreading erythema, crepitus, foul drainage, fever, and leukocytosis demand debridement/amputation plus antibiotics.
• Osteomyelitis: probe-to-bone in an ischemic ulcer, with elevated inflammatory markers and marrow signal change on MRI.
• Myocardial infarction and stroke: PAD marks pan-vascular atherosclerosis; cardiovascular events, not amputation, are the leading cause of death.

Treatment-related

• Reperfusion injury with compartment syndrome (emergency): restored flow floods ischemic muscle with oxygen free radicals and causes edema in a fixed fascial space; pain out of proportion, tense compartment, and pain on passive stretch signal it. Fasciotomy is definitive.
• Rhabdomyolysis with hyperkalemia and AKI (emergency): myoglobin and potassium washout after reperfusion; dark urine, urine dipstick positive for blood without RBCs, markedly elevated CK, peaked T waves.
• **Cholesterol embolization / *blue toe syndrome***: catheter manipulation shears aortic plaque; livedo reticularis with palpable pulses, eosinophilia, low complement, and rising creatinine.
• Access-site complications: pseudoaneurysm (pulsatile mass with to-and-fro Doppler signal), AV fistula (continuous bruit), and retroperitoneal hemorrhage after high femoral puncture (flank pain, hypotension, falling hematocrit — emergency).
• Restenosis, graft thrombosis, and graft infection: neointimal hyperplasia or thrombosis presents as abrupt return of claudication or ALI; infected prosthetic grafts show fever with perigraft fluid or air.
• Drug effects: contrast-associated nephropathy, statin myopathy, bleeding on antiplatelet/dual-pathway therapy, and cilostazol-induced headache, tachycardia, and decompensation of heart failure.

• ABI is the first test, always: an ABI at or below 0.90 confirms PAD. An ABI above 1.40 means non-compressible, medially calcified vessels (diabetes, ESRD) — the next step is a toe-brachial index or Doppler waveform analysis, not angiography.
• Exercise ABI unmasks early disease: classic claudication with a normal resting ABI is the stem that wants post-exercise ABI, where a significant drop confirms flow limitation.
• Angiography (CTA, MRA, or catheter) is for planning revascularization, not for diagnosis. If the stem gives new claudication, the best next step is structured exercise, smoking cessation, a high-intensity statin, and an antiplatelet — not imaging.
• The classic distractor is neurogenic claudication from lumbar spinal stenosis: pain relieved by sitting or leaning forward (shopping-cart sign), worsened by standing still, with normal pulses and normal ABI. Vascular claudication resolves with standing rest alone.
• Leriche syndrome = buttock/hip claudication + erectile dysfunction + absent femoral pulses = aortoiliac occlusion.
• Buerger disease in a man under 45 who smokes heavily, with distal digital ischemia, migratory superficial thrombophlebitis, and corkscrew collaterals on angiography; the only effective therapy is complete tobacco cessation.
• Beta blockers are safe in PAD — refusing one in a PAD patient after MI is a wrong answer. Conversely, cilostazol is contraindicated in heart failure (PDE-3 inhibitors increase mortality).
• Ulcer localization is tested: arterial ulcers are punched-out, painful, over toes and pressure points with absent pulses; venous ulcers sit over the medial malleolus with weeping and hemosiderin staining; neuropathic ulcers sit under the metatarsal heads with callus and preserved pulses.
• Acute limb ischemia: the single best next step is IV unfractionated heparin plus emergent vascular surgery consultation — before imaging.
• PAD is a cardiovascular risk marker: most patients die of MI or stroke, so statin and antiplatelet therapy matter more for survival than any limb intervention.